DexTech Medical (DEX) Q4 2024 earnings summary

Executive summary

• No net sales were recorded for the year or the fourth quarter; operations remain pre-revenue.

• Operating loss for the year was SEK -5.3 million, slightly improved from SEK -5.5 million year-over-year.

• Cash and cash equivalents at year-end were SEK 14.7 million, down from SEK 19.0 million last year.

• The company is funded through Q4 2026 due to reduced costs and previous capital raises.

• Lead candidate OsteoDex advanced in clinical studies for multiple myeloma and prostate cancer.

Financial highlights

• Net sales: SEK 0.0 million for both the quarter and full year (unchanged year-over-year).

• Operating profit: SEK -1.6 million for Q4; SEK -5.3 million for the year.

• Earnings per share: SEK -0.08 for Q4; SEK -0.26 for the year.

• Cash flow for the year: SEK -4.3 million, improved from SEK -6.2 million prior year.

• Equity at year-end: SEK 24.8 million, equity/assets ratio 99%.

Outlook and guidance

• Operations are financed until the end of 2026, with license revenues targeted for future funding.

• Phase 1 myeloma study expected to complete in Q4 2025; further development depends on partnerships.

• Market for multiple myeloma drugs is forecast to reach USD 31 billion by 2026.